Companies /Healthcare

Mannkind Corp

NASDAQ: MNKD Biotechnology
$4.07
▲ $0.12 (+2.91%) today
Markets closed · 9:46pm ET

MNKD at a Glance

Valuation
Market cap
$1.3B
Profitability
Revenue (TTM)
$413.4M
Profit margin
-18.1%
EPS (TTM)
$-0.24
Price
52-week range
$2 – $7
Street target
$8.33

Headquartered in Danbury, CT Fiscal year ends December NASDAQ: MNKD mannkindcorp.com

About MannKind

MannKind Corporation is a biopharmaceutical company focused on cardiometabolic and orphan lung diseases. It specializes in drug-device combinations.

Its commercial products are:
- Afrezza, an inhaled insulin for adults that recently launched a pediatric indication.
- Furoscix, a subcutaneous furosemide for fluid overload in heart failure and chronic kidney disease, acquired through the October 2025 purchase of scPharma. Its newer ReadyFlow presentation was approved and began shipping in September 2026.
- V-Go, a wearable insulin delivery device.

MannKind also earns substantial revenue from United Therapeutics. This comes through manufacturing and collaboration services and a royalty on net sales of Tyvaso DPI, which is built on MannKind's Technosphere dry-powder inhalation platform.

Its development pipeline includes:
- Nintedanib DPI (MNKD-201) for idiopathic pulmonary fibrosis, now entering a global Phase 2 trial.
- Ralinepag DPI (MNKD-1501), to be clinically developed by United Therapeutics, with milestone payments expected in 2027.
- An inhaled short-acting GLP-1 for weight management, licensed with Rose Pharma. Updated

MNKD Coverage

9:41am ET
Health and Healthcare

Big Biotechs Scare Off Short Sellers

The July 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.

Chris Lange
8:45am ET
Health and Healthcare

Short Sellers Wary on Major Biotechs

The January 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.

Chris Lange

Frequently Asked Questions

What does MannKind do?

MannKind Corporation is a biopharmaceutical company focused on cardiometabolic and orphan lung diseases. It specializes in drug-device combinations.

What is the MNKD stock price target?

The Wall Street consensus 12-month price target for MNKD is $8.33.